Pfizer gets priority review for cancer drug label expansion

Pfizer and partner Astellas announced that the FDA has accepted the supplemental New Drug Application looking for label expansion of cancer drug, Xtandi and granted priority review designation.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news